Serum levels of IL-6 and CRP can predict the efficacy of mFOLFIRINOX in patients with advanced pancreatic cancer
暂无分享,去创建一个
F. Zhou | Fan Wang | Sijia He | Feifei Shen | Chuan Liu | Weiguo Zhang | Qi Li | Jingjue Wang
[1] S. Shen-Orr,et al. IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells , 2021, Journal for ImmunoTherapy of Cancer.
[2] C. Haglund,et al. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma , 2021, Scientific Reports.
[3] M. Schuler,et al. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy , 2020, Journal of Cancer Research and Clinical Oncology.
[4] Jie Wu,et al. Prognostic nomogram for predicting survival in patients with high grade endometrial stromal sarcoma: a Surveillance Epidemiology, and End Results database analysis , 2020, International Journal of Gynecological Cancer.
[5] Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.
[6] H. Eguchi,et al. Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study , 2020, Gastric Cancer.
[7] R. Greil,et al. C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients , 2019, Journal of clinical medicine.
[8] P. Yin,et al. [The disease burden of pancreatic cancer in China in 1990 and 2017]. , 2019, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.
[9] N. Tsang,et al. Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact , 2019, Journal of clinical medicine.
[10] Y. Chen,et al. CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer , 2019, BMC Cancer.
[11] F. Greten,et al. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.
[12] T. Rutkowski,et al. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma , 2019, Oncology.
[13] T. Pawlik,et al. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[14] J. D'haese,et al. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer , 2019, Cancers.
[15] Hongwei Zhang,et al. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer , 2018, BMC Gastroenterology.
[16] Zhen Chen,et al. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer , 2018, The Journal of international medical research.
[17] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[18] Wen-quan Wang,et al. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. , 2018, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[19] F. Ursini,et al. Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial , 2018, Pharmacological research.
[20] N. Rifai,et al. Plasma inflammatory cytokines and survival of pancreatic cancer patients , 2018, Clinical and Translational Gastroenterology.
[21] B. Seifert,et al. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy , 2018, British Journal of Cancer.
[22] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[23] T. Ohtsuka,et al. Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence , 2017, World Journal of Surgery.
[24] B. Melichar,et al. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature , 2017, World journal of gastroenterology.
[25] Yanqing Wang,et al. Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone , 2017, Journal of Cancer.
[26] A. Mehrabi,et al. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis , 2017, World journal of gastroenterology.
[27] K. Paik,et al. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern , 2017, Medicine.
[28] Zuqiang Liu,et al. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer , 2017, Annals of Surgical Oncology.
[29] H. Imaoka,et al. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[30] J. Werner,et al. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[31] T. Liang,et al. [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. , 2016, Zhonghua wai ke za zhi [Chinese journal of surgery].
[32] R. Salem,et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer , 2016, British Journal of Cancer.
[33] H. Ueno,et al. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer , 2016, Pancreas.
[34] O. Topolcan,et al. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. , 2016, Neoplasma (Bratislava).
[35] J. Furuse,et al. Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels , 2015, Pancreas.
[36] D. Mutch,et al. Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets , 2015, International Journal of Gynecologic Cancer.
[37] W. Scheithauer,et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. , 2015, The oncologist.
[38] R. Liu,et al. The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer , 2014, Platelets.
[39] S. Daneshmand,et al. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer , 2014, BJU international.
[40] R. Kloiber,et al. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma , 2014, Leukemia & lymphoma.
[41] M. Lindskog,et al. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma , 2014, Medical Oncology.
[42] P. Kornprat,et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients , 2013, British Journal of Cancer.
[43] S. Maithel,et al. Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma , 2013, Pancreas.
[44] J. Lee,et al. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion , 2013, World Journal of Surgical Oncology.
[45] J. Furuse,et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer , 2013, British Journal of Cancer.
[46] M. Chung,et al. Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma , 2013, Yonsei medical journal.
[47] Y. Kanai,et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.
[48] M. Taylor,et al. Ca19-9 and pancreatic cancer: Is it really that good? , 2012, Journal of gastrointestinal oncology.
[49] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[50] D. McMillan,et al. Is Hypoalbuminemia an Independent Prognostic Factor in Patients with Gastric Cancer? , 2010, World Journal of Surgery.
[51] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[52] N. Shimizu,et al. Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas , 2005, Cancer science.
[53] B. Stewart,et al. World Cancer Report , 2003 .
[54] V. Keim,et al. Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer , 2000, British Journal of Cancer.
[55] C. Gebhardt,et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma , 2000, Langenbeck's Archives of Surgery.
[56] Jeong Hee Lee,et al. Monoclonal Antibodies against Helicobacter pylori Cross‐React with Human Tissue , 1997, Helicobacter.